ECU
BIO icon

Eisler Capital (UK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Eisler Capital (UK)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,132
Closed -$1.01M – 610
2023
Q4 		$1.01M Buy
+3,132
New +$982K 0.01% 501

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Eisler Capital (UK)'s BIO Position: Q1 2024 in Review

Eisler Capital (UK) sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 3,132 shares — an estimated $1.01M sold.

Eisler Capital (UK) first reported a position in BIO in Q4 2023 and held it in 1 quarter. The position peaked at $1.01M in Q4 2023. 466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

  • Eisler Capital (UK) reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
  • Eisler Capital (UK) sold 3,132 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $1.01M.
  • Eisler Capital (UK) first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and held it in 1 quarter.
  • Eisler Capital (UK)'s Bio-Rad Laboratories Class A position peaked at $1.01M in Q4 2023.
  • 466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Eisler Capital (UK)'s 13F filing for Q1 2024, filed 14 May 2024.